MedTrace Logo

Extensively Hydrolyzed Formula: Hypoallergenicity

NCT01278446 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL

Last updated 2013-11-04

No results posted yet for this study

Summary

The primary objective of this clinical trial is to determine whether a new extensively hydrolyzed infant formula is hypoallergenic.

Conditions

  • Food Hypersensitivity

Interventions

OTHER

Extensively hydrolyzed, whey protein infant formula

New hydrolyzed formula

OTHER

Extensively hydrolyzed, casein protein infant formula

Commercially available hydrolyzed infant formula

Sponsors & Collaborators

  • Société des Produits Nestlé (SPN)

    lead INDUSTRY

Principal Investigators

  • Jose Saavedra, MD · Nestle Nutrition

  • Anna Nowak-Wegrzyn, MD · Mount Sinai Department of Pediatrics

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
2 Months
Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2012-06-30
Completion
2012-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01278446 on ClinicalTrials.gov